Tipranavir is a new protease inhibitor that has been shown to be effective in
suppressing HIV in patients with extensive PI resistance. It is boosted with
a low dose of ritonavir. The phase III study is starting now and enrolling
patients. This link will take you to the study criteria and study sites, and
a telephone number you can call for information.
